- 40 Downloads
▴ The triple combination tablet containing lamivudine (150mg), zidovudine (300mg) and abacavir (300mg, as abacavir sulfate) is a new formulation of three nucleoside analogue reverse transcriptase inhibitors.
▴ Two studies in treatment-naive patients (one double-blind, one nonblind) have reported that lamivudine/zidovudine (dual combination tablet) plus abacavir showed efficacy similar to that of lamivudine/zidovudine plus indinavir. In both studies, similar numbers of patients in each treatment group had plasma HIV RNA levels <400 copies/mL at week 48 (51% vs 51% and 64% vs 50%).
▴ In treatment-experienced patients with baseline plasma HIV RNA levels <50 copies/mL, switching to lamivudine/zidovudine/abacavir (triple combination tablet) was as effective as remaining on highly active antiretroviral treatment (mainly protease inhibitor [PI]-based). Virological failure, the primary endpoint, defined as two consecutive plasma HIV RNA values >400 copies/mL, was reported in 22% of patients in both treatment groups at week 48.
▴ Treatment-naive patients receiving lamivudine/zidovudine/abacavir combination therapy experienced several adverse events, including nausea, malaise/fatigue and vomiting.
KeywordsLamivudine Zidovudine Abacavir Virological Failure Amprenavir
- 3.Panel on Clinical Practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.hivatis.org [Accessed 2002 Feb 4]
- 4.Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society —USA panel. 2000 Jan 19; 283: 381–90Google Scholar
- 7.Rutherford GW, Feldman KA, Kennedy GE. Three- or four-versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev 2000; (2): CD002037Google Scholar
- 8.Trizivir® (abacavir sulphate, lamivudine and zidovudine) tablets. US product information. Research Triangle Park (NC): GlaxoSmithKline, 2001 MayGoogle Scholar
- 11.Weller S, Radomski KM, Lou Y, et al. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000 Aug; 44(8): 2052–60PubMedCrossRefGoogle Scholar
- 14.Miller V, Larder B. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001; 6 Suppl. 3: 25–44Google Scholar
- 17.Lanier ER, Hellmann H, Scott J, et al. Determination of a clinically relevant phenotypic resistance “cutoff” for abacavir using the PhenoSense Assay [abstract]. 8th Conf Retroviruses Opportun Infect; 2001 Feb 4–8; Chicago (IL)Google Scholar
- 18.Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI associated mutations and response to subsequente therapy for patients on failing ABC/COM (CNA3005) [abstract no. 448]. 8th Conf Retroviruses Opportun Infect; 2001 Feb 4–8; Chicago (IL), 5Google Scholar
- 20.Ait-Khaled M, Rakik A, Griffin P, et al. Viral rebound during 48 weeks of abacavir/lamivudine/zidovudine combination therapy in antiretroviral-naive subjects is infrequent with emergent virus showing a limited number of NRTI resistance mutations [abstract no. 76]. Antiviral Ther 1999 Jun; 4 Suppl. 1: 52Google Scholar
- 22.Katlama C, Fenske S, Gazzard B, et al. Switch to Trizivir versus continued HAART provides equivalent HIV-1 RNA suppression at 48 weeks (TRIZAL-AZL30002) [abstract no. I-671]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL), 324Google Scholar
- 23.Lafeuillade A, Mamet JP, Chéret A, et al. Comparison of the metabolic disorders and clinical lipodystrophy 48 weeks after switching from highly active antiretroviral therapy to Trizivir versus continued highly antiretroviral therapy (TRIZAL: AZL30002) [abstract no. 28]. Antiviral Ther 2001 Oct; 6 Suppl. 4: 20Google Scholar
- 24.Walli R, Huster K, Goebel FD. Effect of switching from protease inhibitors to abacavir on insulin sensitivity and fasting lipids: 12-month follow-up [abstract no. P43]. Antiviral Ther 2000 Sep; 5 Suppl. 5: 48Google Scholar
- 26.Cremieux AC, Katlama C, Gillotin C, et al. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy 2001 Apr: 21(4): 424–30PubMedCrossRefGoogle Scholar
- 28.Vibhagool A, Cahn P, Schechter M, et al. Abacavir/combivir is comparable to indinavir/combivir in HIV-1 infected antiretroviral therapy naive adults: preliminary results of a 48-week open label study (CNA3014) [abstract no 63]. 1st International Aids Society Conference; 2001 Jul 8–11; Buenos Aires, 102Google Scholar
- 30.Rozenbaum W, Katlama C, Massip P, et al. Treatment intensification with abacavir in HIV-1 infected adults with previous 3TC/ZDV antiretroviral treatment; 48 week results (CNAB3009) [abstract plus poster]. 7th European Conference on Clinical Aspects and Treatment of HIV Infection; 1999 Oct 23; Lisbon, 91Google Scholar
- 31.Matheron S, Vezinet BV, Katlama C, et al. 48 week results of the CNAF3007/Ecureuil open label study: efficacy and safety of the triple nucleoside combination combivir/abacabir versus combivir/nelfinavir as first-line antiretroviral therapy in HIV-1 infected adults [abstract no. P15]. AIDS 2000 Oct; 14 Suppl. 2: S21Google Scholar
- 32.Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001 Aug 17; 15(12): 1517–26PubMedCrossRefGoogle Scholar
- 35.Trizivir® (abacavir sulphate, lamivudine and zidovudine) tablets. Product monograph. Research Triangle Park (NC): GlaxoSmithKline, 2002 JunGoogle Scholar